Progestins and Breast Cancer Stem Cells
Gene expression profiling separates breast cancers into two major subtypes: estrogen receptor-positive (ER ϩ ), progesterone re- The cancer stem cell theory proposes that tumors originate from mitotically quiescent stem cells that are capable of selfrenewal, while at the same time spawning proliferative, committed progenitor cells that differentiate and expand into the clinically significant tumor mass (2) . In the human breast, normal stem cells have been defined by expression of epithelial-specific antigen (ESA) and ␣6 integrin (CD49f) by markers that include Musashi, the Polycomb group repressor Bmi-1, and CK5/6 or by label-retention and side-population properties (reviewed in Ref. (9).
Of interest was the effect of progestins, but not estrogens, on this pathway (9) . Treatment of colonies for 24 h with progesterone, or the synthetic progestin commonly used for hormone replacement therapies (HRT), medroxyprogesterone acetate (MPA; Depo Provera), led to an increase in the ER Ϫ , PR Ϫ , CK5 This happens in 24 h or less and does not require proliferation. Up-regulation by progestins of cells with stem-like properties sets the stage for their subsequent differentiation into transient intermediates/progenitors and restoration of ER and PR in a step that is not hormone regulated, followed by resumption of growth under the control of estrogens. Our hypothesis thus relegates to progestins the function of stem cell reactivation without concomitant proliferation, while leaving to estrogens their well-known mitogenic/proliferative functions (see Fig. 2 ). 
Progestins, occult breast cancers, and HRT
The combined estrogen plus progestin (EϩP) arm of the Women's Health Initiative menopausal HRT trial was stopped prematurely in 2002, because of failure to demonstrate an overall health benefit and because of an increased risk of invasive, ER ϩ breast cancer, compared with the estrogen-only arm (10) . The data have been the subject of considerable controversy since then due to concerns about the statistical analytic methods employed, the high proportion of elderly women begun on hormones several years after menopause, hormone restriction to conjugated equine estrogens plus MPA, and because the results contravened prevailing views that progestins should be protective. Nevertheless, subsequent studies have tended to support the notion that EϩP increases the risk of developing clinically relevant breast cancers (11) (12) (13) or stimulates growth of tumor microdeposits in breast cancer survivors (14) .
Why does addition of progestins to estrogens increase breast cancer risk? Various explanations have been advanced: that progestins cause cancer directly, that they enhance the effect of carcinogens, that progestins are antiproliferative in the uterus but proliferative in the breast, and that effects of progestins are subject to lifestyle factors like diet and alcohol use or to genetic factors, reproductive history, environmental exposure, mammographic features, and the like (reviewed in 15). Some of these explanations remain unproven; others may be too complex and confounding for practical clinical decision making.
Is there another explanation? Among seven autopsy series of women not known to have breast cancer during life, the median prevalence of invasive breast cancer was 1.3% (range, 0 -1.8%), and the median prevalence of ductal carcinoma in situ was 8.9% (range, 0 -14%). Importantly, this occult disease was found only in women over 40 yr of age (16) . A separate study in 1987 sought to analyze the radiographic detectability of such occult disease. The authors also concluded that it was restricted to women over 39 yr old but found, discouragingly, that 82% of such tumors would have been mammographically undetectable in life by the methods then in use and were only detectable histologically postmortem (17) . Clearly, a substantial reservoir (16) of early breast cancers is undetected in women who are at an age when HRT is often prescribed. Importantly, younger women who are more likely to be using oral contraceptives that include progestins appear not to be susceptible to this problem. In a related issue, women presumed to have recovered from breast cancer may harbor occult nanometastases that are mammographically undetectable and may even escape routine microscopy (18) . Use of systemic progestins in such patients should be viewed with caution.
Hypothesis
Based on these studies, and our discovery that progestins, but not estrogens, reactivate stem-like properties in breast cancer cells (9), we propose a simple and potentially testable explanation for the effects of progestins in HRT. Namely, that women who develop breast cancer while on EϩP had undiagnosed breast cancer before the start of HRT, and the progestin component reactivated occult, possibly even dormant (17) , breast cancer stem cells. Importantly, the experimental data indicate that estrogen alone is incapable of such an effect. Once reactivated, however, mitogens like estrogen can expand the tumor cells. The data (9) also suggest that small, nascent, preinvasive disease, like atypical intraductal hyperplasia, ductal carcinoma in situ, or nanometastases, are at greatest risk of stem cell reactivation by systemic progestins. If our hypothesis is correct, it would suggest that 1) sensitive methods need to be developed to detect occult, possibly dormant, breast cancers; 2) women should be screened for preexisting malignancies by the best available methods before the start of HRT and, if harboring such disease, be excluded from regimens that include systemic progestins; and 3) given current limitations of screening methods, patients should be fully informed about the benefits and risks they face when they are prescribed HRTs that include systemic progestins. Instead, local progestin delivery, as with intrauterine systems, could provide the desired protective effects of these hormones in the uterus, without their possible harmful effects in the breast (19) .
